Bladder cancer screening and future directions in urine-based markers for bladder urothelial carcinoma

Jose A. Karam, Yair Lotan, Shahrokh F. Shariat

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

At present, bladder cancer screening is not an accepted standard of care; however, there is potential for non-invasive screening for this disease. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors and is not cost-effective for screening. Use of hemoglobin dipstick has been utilized for screening but suffers from a low positive predictive value. An accurate bladder tumor marker would be useful for both screening of high-risk populations and for monitoring of patients with a history of bladder cancer to help identify recurrence early and prevent disease progression. A number of markers that take advantage of exfoliated cells in the urine for detection of cell surface antigens, nuclear morphology, or gene expression as well as markers for detection of excreted proteins have been studied in bladder cancer. In our previous review, we have discussed cytology and commercially available FDA-approved urine markers. Herein, we review the potential for bladder cancer screening as well as the most promising urine-based markers that are currently under investigation.

Original languageEnglish (US)
Pages (from-to)116-120
Number of pages5
JournalLaboratory Medicine
Volume38
Issue number2
DOIs
StatePublished - 2007

Fingerprint

Early Detection of Cancer
Urinary Bladder Neoplasms
Screening
Urinary Bladder
Urine
Carcinoma
Cytology
Cell Biology
Physiologic Monitoring
Surface Antigens
Standard of Care
Tumor Biomarkers
Disease Progression
Hemoglobins
Gene expression
Direction compound
Tumors
Gene Expression
Costs and Cost Analysis
Recurrence

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Bladder cancer screening and future directions in urine-based markers for bladder urothelial carcinoma. / Karam, Jose A.; Lotan, Yair; Shariat, Shahrokh F.

In: Laboratory Medicine, Vol. 38, No. 2, 2007, p. 116-120.

Research output: Contribution to journalArticle

@article{0831b00c384741eda7876e4b5ac0ec8b,
title = "Bladder cancer screening and future directions in urine-based markers for bladder urothelial carcinoma",
abstract = "At present, bladder cancer screening is not an accepted standard of care; however, there is potential for non-invasive screening for this disease. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors and is not cost-effective for screening. Use of hemoglobin dipstick has been utilized for screening but suffers from a low positive predictive value. An accurate bladder tumor marker would be useful for both screening of high-risk populations and for monitoring of patients with a history of bladder cancer to help identify recurrence early and prevent disease progression. A number of markers that take advantage of exfoliated cells in the urine for detection of cell surface antigens, nuclear morphology, or gene expression as well as markers for detection of excreted proteins have been studied in bladder cancer. In our previous review, we have discussed cytology and commercially available FDA-approved urine markers. Herein, we review the potential for bladder cancer screening as well as the most promising urine-based markers that are currently under investigation.",
author = "Karam, {Jose A.} and Yair Lotan and Shariat, {Shahrokh F.}",
year = "2007",
doi = "10.1309/FG6FGPRLDKU3FFP4",
language = "English (US)",
volume = "38",
pages = "116--120",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Bladder cancer screening and future directions in urine-based markers for bladder urothelial carcinoma

AU - Karam, Jose A.

AU - Lotan, Yair

AU - Shariat, Shahrokh F.

PY - 2007

Y1 - 2007

N2 - At present, bladder cancer screening is not an accepted standard of care; however, there is potential for non-invasive screening for this disease. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors and is not cost-effective for screening. Use of hemoglobin dipstick has been utilized for screening but suffers from a low positive predictive value. An accurate bladder tumor marker would be useful for both screening of high-risk populations and for monitoring of patients with a history of bladder cancer to help identify recurrence early and prevent disease progression. A number of markers that take advantage of exfoliated cells in the urine for detection of cell surface antigens, nuclear morphology, or gene expression as well as markers for detection of excreted proteins have been studied in bladder cancer. In our previous review, we have discussed cytology and commercially available FDA-approved urine markers. Herein, we review the potential for bladder cancer screening as well as the most promising urine-based markers that are currently under investigation.

AB - At present, bladder cancer screening is not an accepted standard of care; however, there is potential for non-invasive screening for this disease. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors and is not cost-effective for screening. Use of hemoglobin dipstick has been utilized for screening but suffers from a low positive predictive value. An accurate bladder tumor marker would be useful for both screening of high-risk populations and for monitoring of patients with a history of bladder cancer to help identify recurrence early and prevent disease progression. A number of markers that take advantage of exfoliated cells in the urine for detection of cell surface antigens, nuclear morphology, or gene expression as well as markers for detection of excreted proteins have been studied in bladder cancer. In our previous review, we have discussed cytology and commercially available FDA-approved urine markers. Herein, we review the potential for bladder cancer screening as well as the most promising urine-based markers that are currently under investigation.

UR - http://www.scopus.com/inward/record.url?scp=58149478358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149478358&partnerID=8YFLogxK

U2 - 10.1309/FG6FGPRLDKU3FFP4

DO - 10.1309/FG6FGPRLDKU3FFP4

M3 - Article

VL - 38

SP - 116

EP - 120

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 2

ER -